Every material Form 8-K TACTILE SYSTEMS TECHNOLOGY INC has filed with the SEC since July 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tactile Medical reported third-quarter 2026 results on November 2, 2026. Revenue and lymphedema sales grew year over year, but net income and diluted earnings per share fell as operating expenses rose 13%. The company raised its full-year 2026 Adjusted EBITDA guidance by $1 million at both ends of the range and kept its revenue guidance unchanged.
Total revenue rose 7% year over year to $91.9 million; lymphedema sales rose 13% to $81.8 million, while airway clearance sales fell 25% to $10.0 million.
Net income was $7.2 million, or $0.31 per diluted share, down from $8.2 million, or $0.36, in Q3 2025.
Full-year 2026 Adjusted EBITDA guidance is now $50 million to $52 million, up from $49 million to $51 million; revenue guidance of $360 million to $366 million was unchanged.
The company repurchased $6.2 million of stock in the quarter, leaving $12.5 million under its $25.0 million program, which expires November 3, 2027.
Tactile Medical reported second-quarter 2026 revenue up 9% year-over-year to $85.7 million and net income of $7.8 million, or $0.34 per diluted share, compared with $3.2 million, or $0.14 per diluted share, a year earlier. The company lowered the top end of its full-year 2026 revenue forecast to $360 million to $366 million from $360 million to $368 million, citing temporary inventory dynamics tied to the AffloVest launch, while keeping its adjusted EBITDA outlook of $49 million to $51 million unchanged. Shareholders get profit growth alongside a narrower sales outlook.
Q2 2026 total revenue was $85.7 million, up from $78.9 million; airway clearance sales fell 7% on temporary inventory dynamics at a few large DME providers.
Q2 2026 net income was $7.8 million, or $0.34 per diluted share, versus $3.2 million, or $0.14 per diluted share, in Q2 2025.
Full-year 2026 revenue guidance is now $360 million to $366 million, versus the prior $360 million to $368 million.
Adjusted EBITDA guidance of $49 million to $51 million was maintained; cash was $69.9 million as of June 30, 2026.
Tactile Systems Technology (Tactile Medical) entered an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device, covering Department of Veterans Affairs and Department of Defense patients. The company paid an upfront $3 million and committed to certain minimum purchase obligations and marketing support, and the filing gives no revenue or financial outlook for the deal.
Exclusive U.S. distribution rights for MyoSleeve within the VA and DoD systems, announced July 13, 2026
Upfront payment of $3 million to ElastiMed, plus undisclosed minimum purchase and marketing commitments
MyoSleeve has FDA 510(k) clearance for chronic swelling, including chronic edema, lymphedema and venous insufficiency
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TACTILE SYSTEMS TECHNOLOGY INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →